SafeBoosC III试验详细统计分析计划:基于脑氧监测指导治疗与常规治疗在极早产儿中的多国随机临床试验
SafeBoosC III是一项研究者发起的多国随机平行对照III期试验,评估基于脑近红外光谱监测指导治疗与常规治疗相比对极早产儿的获益与风险。本文预先发布详细统计分析计划以防止结局报告偏倚和数据驱动分析,主要结局为36周矫正胎龄时死亡或严重脑损伤的复合结局,主要分析采用混合模型逻辑回归校正分层变量。
要点
- 主要结局为36周矫正胎龄死亡或严重脑损伤的复合结局。
- 主要分析在意向性治疗人群中使用混合模型逻辑回归校正分层变量。
- 双胎组内相关系数不纳入主要分析,但将进行敏感性分析。
核心结论
- 本统计分析计划在数据分析前制定并发布,旨在防止结局报告偏倚和数据驱动分析。
- 模拟研究提示纳入多胎不太可能显著影响干预效应评估,故主要分析不考虑双胎组内相关系数。
研究设计与样本
- SafeBoosC III为研究者发起的、随机、多国、实用性III期试验,采用平行组结构。
- 随机化按1:1分层,分层因素为新生儿重症监护病房和胎龄(<26周与≥26周)。
关键数值与推荐
- 主要结局为36周矫正胎龄时死亡或严重脑损伤的复合结局。
- 主要分析在意向性治疗人群中进行,采用混合模型逻辑回归校正分层变量。
- 主要分析不考虑双胎组内相关系数,但将进行敏感性分析。
临床怎么用
- 统计分析计划预先发布,可用于指导该试验主要结果的解读和质量评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infants born extremely preterm are at high risk of dying or suffering from severe brain injuries. Treatment guided by monitoring of cerebral oxygenation may reduce the risk of death and neurologic complications. The SafeBoosC III trial evaluates the effects of treatment guided by cerebral oxygenation monitoring versus treatment as usual. This article describes the detailed statistical analysis plan for the main publication, with the aim to prevent outcome reporting bias and data-driven analyses. METHODS/DESIGN: The SafeBoosC III trial is an investigator-initiated, randomised, multinational, pragmatic phase III trial with a parallel group structure, designed to investigate the benefits and harms of treatment based on cerebral near-infrared spectroscopy monitoring compared with treatment as usual. Randomisation will be 1:1 stratified for neonatal intensive care unit and gestational age (lower gestational age (< 26 weeks) compared to higher gestational age (≥ 26 weeks)). The primary outcome is a composite of death or severe brain injury at 36 weeks postmenstrual age. Primary analysis will be made on the intention-to-treat population for all outcomes, using mixed-model logistic regression adjusting for stratification variables. In the primary analysis, the twin intra-class correlation coefficient will not be considered. However, we will perform sensitivity analyses to address this. Our simulation study suggests that the inclusion of multiple births is unlikely to significantly affect our assessment of intervention effects, and therefore we have chosen the analysis where the twin intra-class correlation coefficient will not be considered as the primary analysis. DISCUSSION: In line with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines, we have developed and published this statistical analysis plan for the SafeBoosC III trial, prior to any data analysis. TRIAL REGISTRATION: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.
引用
- Hansen ML, Pellicer A, Gluud C, et al. Detailed statistical analysis plan for the SafeBoosC III trial: a multinational randomised clinical trial assessing treatment guided by cerebral oxygenation monitoring versus treatment as usual in extremely preterm infants. Trials. 2019. PMID: 31856902. doi:10.1186/s13063-019-3756-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。